# QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

> **NCT07708272** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** TQ05105 tablets
- **DRUG:** Placebo tablets
- **DRUG:** Moxifloxacin Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT07708272
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708272, "QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07708272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*